Date: 2015-03-20
Type of information: Development agreement
Compound: gene therapies based on viral vector cellular transduction
Company: GSK (UK) Molmed (Italy)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: collaboration development manufacturing production
Action mechanism: gene therapy
Disease:
Details: * On March 20, 2015, MolMed announces that it has entered into a strategic agreement with GSK under which MolMed will supply development, manufacturing and technology transfer services aimed at the clinical application of gene therapies based on viral vector cellular transduction. As part of the agreement, MolMed will provide its expertise in process development and its manufacturing competencies and capacity for the production of viral vectors and cell transduction. This new agreement with GSK follows those signed in 2011 and 2013 and strengthens the collaboration between the two companies in the field of gene therapies.
Financial terms: Under the terms of the agreement, MolMed would be eligible for a minimum of € 34 million in the form of upfront, milestones, services and supply, over the next five years. In particular, GSK will pay to MolMed during the next 12 months starting from the effective date of the agreement an amount related to the upfront and milestones equal to approximately € 6 million.
Latest news:
